No significant differences seen in diastolic blood pressure, augmentation index, DAS28-CRP
MONDAY, Sept. 15, 2025 (HealthDay News) — For patients with rheumatoid arthritis (RA), methotrexate significantly reduces systolic blood pressure (SBP), according to a study published online July 31 in the Annals of Medicine.
Arduino A. Mangoni, M.D., Ph.D., from Flinders University in Australia, and colleagues conducted a controlled comparative study of treatment-naive newly diagnosed RA patients commenced on subcutaneous methotrexate (group 1; 31 patients) or the disease-modifying antirheumatic drug comparator sulfasalazine (group 2; 31 patients). At baseline and after one and six months of treatment, clinic SBP and diastolic BP (DBP) and augmentation index were measured.
The researchers found that after six months, patients in group 1 had significantly lower SBP than those in group 2 (−7.4 mm Hg). No significant between-group differences were seen in DBP, augmentation index, or Disease Activity Score-28 C-reactive protein. During methotrexate treatment, there was a significant effect of single nucleotide polymorphisms rs1801133 (methyl tetrahydrofolate reductase) and rs2231142 (ATP-binding cassette subfamily G member 2) on BP changes.
“This kind of reduction is considered meaningful because even a small drop in blood pressure can lower the risk of serious heart problems like heart attacks and strokes,” Mangoni said in a statement.
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL 
Rheumatic Immune-Related AEs With Immune Checkpoint Inhibitors More Severe Than Previously Reported 
Mortality in Injured Children Linked to Higher SBP Thresholds Than Those That Define Hypotension 
Eating More Whole Grains Daily Linked to Cardiometabolic Benefits 
Intensive BP Lowering Reduces Recurrent Stroke After Intracerebral Hemorrhage 
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians 
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death 
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines 
